Prostate cancer (PCa), a complex entity with a highly variable clinical course, has long relied on biomarkers, notably prostate-specific antigen (PSA), for diagnostic purposes over the past two decades (4, 5). The gene discussed is KLK3; the disease is posterior cortical atrophy.